WuXi Diagnostic was established in early 2018 as a joint venture between New WuXi Life Science Investment Limited and Mayo Clinic, an operation entity that provides clinical diagnostic services to China market. The company integrates the excellent operational capabilities of WuXi AppTec and the clinical and testing experience of Mayo Clinic. It focuses on the development of advanced diagnostic technologies to create a world-leading clinical special diagnostic platform and integrated research and development of clinical diagnostic reagents and products platform, establish a comprehensive large-scale clinical testing data center, and empower Chinese medical institutions. At the same time, it will empower global scientists to accelerate the transformation of innovative ideas in the field of in vitro diagnostics into commercial reality for the benefit of society.
Equal Opportunity Employer Minorities/Women/Veterans/Disabled